JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2008, 57(3):115-118

Synthesis of 2-{3-[4-(4-fluorophenyl)-1-piperazinyl]-2-hydroxy-propoxy}-phenylcarbamic acid alkylesters and in vitro evaluation of their ß-antiadrenergic and vasodilatative activities

T. Goněc1,*, E. Račanská2, J. Csöllei1
1 Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav chemických léčiv
2 Univerzita Komenského v Bratislave, Farmaceutická fakulta, Katedra farmakológie a toxikológie

In effort to obtain effective compounds able to favourably influence pathologically changed cardiovascular functions, such as hypertension and ischemic cardiac disease, a new series of aryloxyaminopropanols were synthesized. Four of the compounds, which differ in the alkyl substitution of phenylcarbamate (methyl, ethyl, propyl, butyl), were chosen for basic in vitro pharmacological analyses. In experiments on the isolated spontaneously beating guinea pig atria all compounds at conc. of 1.0.10-6 mol.l-1 decreased the basic heart rate (7.6-13.6%) and inhibited the positive chronotropic effect of isoprenaline (pA2 = 6.28-6.81). The compounds manifest only a slight relaxation effect on KCl pre-contracted aortal strips of rats (not until conc. of 1.0.10-5 mol.l-1). The compounds with propyl and butyl substitution appear more effective than the methyl and ethyl derivatives.

Keywords: aryloxyaminopropanols; β-antiadrenergic; isolated atria; isolated aorta

Received: April 18, 2008; Accepted: April 30, 2008; Published: March 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Goněc T, Račanská E, Csöllei J. Synthesis of 2-{3-[4-(4-fluorophenyl)-1-piperazinyl]-2-hydroxy-propoxy}-phenylcarbamic acid alkylesters and in vitro evaluation of their ß-antiadrenergic and vasodilatative activities. Čes. slov. farm. 2008;57(3):115-118.
Download citation

References

  1. Fölsch, U. R., Kochisek, K., Schmidt, R. F.: Patologická fyziologie. Praha, Grada Publishing, 2003, 138-143.
  2. Lülmann, H., Mohr, K., Wehling, M.: Farmakologie a toxikologie. Praha, Grada Publishing, 2004, 97-121.
  3. Marek, J. et.al.: Farmakoterapie vnitřních nemocí. Praha, Grada Publishing, 2005, 87-110.
  4. Čelková, H., Csöllei, J., Čižmárik, J. et al.: Čes. slov. Farm., 1996; 45, 255-259.
  5. Mlynárová, J., Čelková, H., Račanská, E.: Čes. slov. Farm., 1996; 45, 260-264.
  6. Račanská, E., Kurfürst, P., Csöllei, J., Švec, P.: Acta Facult. Pharm. Univ. Comenianae, 2004; 51, 182-191.
  7. Csöllei, J., Borovanský, A., Beneš, L. et al.: Čes. slov. Farm., 1982; 31, 229-235.
  8. Van Rosum, J. N.: Arch. Int. Pharmacol. Ther., 1963; 143, 299-330.




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.